


IN THE CLAIMS:

1. (Currently amended) A soft capsule comprising:

(a) a shell comprising gelatin, wherein said shell encapsulates

(b) a solution pharmaceutical formulation comprising about 1% to about 45% by weight of an active compound having ~~the~~ a structural formula



and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable solvent selected from the group comprising propylene glycol, polyethylene glycol 400, glycofurool, and mixtures thereof.

2.-3. (Cancelled)

4. (Currently amended) The capsules of claim 3 22 wherein the active compound is present as a free drug.

5.-7. (Cancelled)

8. (Currently amended) The capsules of claim ~~6~~ 1 wherein the pharmaceutically acceptable carrier further comprises a polyvinylpyrrolidone.

9. (Currently amended) The capsules of claim ~~2~~ 1 wherein the pharmaceutical formulation comprises about 2% to about 2.8% by weight of the active compound, about 3% to about 8% by weight propylene glycol, and about 90% to about 95% by weight polyethylene glycol 400.

10.-11. (Cancelled)

12. (Currently amended) The capsules of claim ~~10~~ 22 wherein the suspending agent comprises a saturated polyglycolized glyceride.

13. (Currently amended) The capsules of claim ~~10~~ 22 wherein the suspending agent comprises a saturated polyglycolized glyceride and the solvent comprises C₈-C₁₀ monoglycerides.

14. (Currently amended) The capsules of claim ~~10~~ 22 wherein the pharmaceutically acceptable carrier further comprises a surfactant.

15. (Currently amended) The capsules of claim 3 22 wherein the pharmaceutical formulation comprises about 3% to about 8% by weight of the active compound, about 5% to about 8% by weight propylene glycol, about 10% to about 60% by weight of C₈-C₁₀ monoglycerides, and about 30% to about 75% by weight of a polyglycolyzed glyceride.

16. (Currently amended) The capsules of claim 1 or 22 wherein the active compound is present in an amount of about 1 to about 20 mg per capsule.

17. (Currently amended) The capsules of claim 1 or 22 wherein the active compound is present in an amount of about 2 to about 20 mg per capsule.

18. (Currently amended) The capsules of claim 1 or 22 wherein the active compound is present in an amount of about 5 to about 15 mg per capsule.

19. (Currently amended) The capsules of claim 1 or 22 wherein the active compound is present in an amount of about 10 mg per capsule.


20. (Currently amended) A method of treating sexual dysfunction in a patient in need thereof comprising administering to the patient a capsule of ~~any of claims~~ claim 1 to 19 or 22.

21. (Cancelled)

22. (New) A soft capsule comprising:

(a) a shell comprising gelatin, wherein said shell encapsulates

(b) a suspension pharmaceutical formulation comprising about 1% to about 45% by weight of solid particles of an active compound having a structural formula



and a pharmaceutically acceptable carrier comprising
(i) a pharmaceutically acceptable solvent selected from the group consisting of polyethylene glycol 400, propylene glycol, glycofurol, a C₈-C₁₀ monoglyceride, and mixtures thereof, and (ii) a suspending agent.

23. (New) The method of claim 20 wherein the sexual dysfunction is male erectile dysfunction.

24. (New) The method of claim 20 wherein the sexual dysfunction is female arousal disorder.